282 related articles for article (PubMed ID: 24517243)
1. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
2. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
6. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
7. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
8. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
9. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
12. Cutaneous toxicities of RAF inhibitors.
Anforth R; Fernandez-Peñas P; Long GV
Lancet Oncol; 2013 Jan; 14(1):e11-8. PubMed ID: 23276366
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
14. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
15. Nilontinib induced keratosis pilaris atrophicans.
Khetarpal S; Sood A; Billings SD
Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617940
[TBL] [Abstract][Full Text] [Related]
16. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
17. Cutaneous side effects of vemurafenib: a case report and discussion.
Shea SM; Boyd K; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
19. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
20. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]